Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dilevalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 13/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 13/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 11/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 13/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 12/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL29687428 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL3499242 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL7273474 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL4582 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10356800 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10882744 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL41231 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL41230 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10450118 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL9614383 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2978 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-20210330750-A1 | LACTATE-PROTECTED HYPOGLYCEMIA TO TREAT GLYCOLYSIS DEPENDENT PATHOLOGICAL CONDITIONS, IN PARTICULAR CANCER | LACA MEDICAL B.V. (NL) | 2021-10-28 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3843776-A1 | LACTATE-PROTECTED HYPOGLYCEMIA TO TREAT GLYCOLYSIS DEPENDENT PATHOLOGICAL CONDITIONS, IN PARTICULAR CANCER | LaCa Medical BV (NL) | 2021-07-07 | — | — | EP | claimed |
| US-20200390858-A1 | Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases | NGM BIOPHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | claimed |
| WO-2020214753-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM BIOPHARMACEUTICALS, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| WO-2020043708-A1 | LACTATE-PROTECTED HYPOGLYCEMIA TO TREAT GLYCOLYSIS DEPENDENT PATHOLOGICAL CONDITIONS, IN PARTICULAR CANCER | LACA MEDICAL B.V. (NL) | 2020-03-05 | — | — | WO | claimed |
| EP-3616714-A1 | LACTATE-PROTECTED HYPOGLYCEMIA TO TREAT GLYCOLYSIS DEPENDENT PATHOLOGICAL CONDITIONS, IN PARTICULAR CANCER | LaCa Medical BV (NL) | 2020-03-04 | — | — | EP | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-4658060-A | Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide | SCHERING CORPORATION (US) | 1987-04-14 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0092787-B1 | PROCESS FOR THE PREPARATION OF A PHENYLALKYLAMINOETHYLSALICYLAMIDE | SCHERING CORPORATION (US) | 1986-08-27 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0092787-A1 | Process for the preparation of a phenylalkylaminoethylsalicylamide | SCHERING CORPORATION (US) | 1983-11-02 | — | — | EP | claimed |
| EP-0009702-B1 | A PHENYLALKYLAMINOETHYLSALICYLAMIDE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | SCHERING CORPORATION (US) | 1981-11-04 | — | — | EP | claimed |
| EP-0009702-A1 | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it | SCHERING CORPORATION (US) | 1980-04-16 | — | — | EP | claimed |